Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.

Paclitaxel-based and nab-paclitaxel-based chemotherapy produced similar 5-year outcomes in patients with high-risk, HR+, HER2- early breast cancer.

Modified Radiation-Induced Skin Reaction Assessment Scale scores were lower with Mepitel Film than with standard care. The use of Mepitel Film, a silicone-based dressing applied to skin, can reduce ...

Omitting axillary SLNB does not impact outcomes in patients with early invasive breast cancer undergoing breast-conserving surgery, data suggest.

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

The 36-month overall survival rate was 74% in the belantamab mafodotin arm and 60% in the daratumumab arm. Belantamab ...

Imlunestrant, given alone or in combination with abemaciclib, has demonstrated efficacy in patients with ER+, HER2- advanced breast cancer.

Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.

This page includes links to articles highlighting the top skin cancer research published on Cancer Therapy Advisor in 2024.

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.